ESCRT may function as a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancer

BackgroundStudies have shown that ESCRT genes affect cell aging, immune environment, and tumors. BRCA was used to explore its effects on tumor prognosis and therapy.MethodsThe data sets of Cancer Genome Atlas (TCGA), Genome-Tissue Expression Plan (GTEX), Human Protein Mapping (HPA), Gene Expression...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiao-rui Chen, Xue-ying Tan, Zong-liang Zhang, Jiang-shui Yuan, Wei-qing Song
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1531940/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850206306696167424
author Xiao-rui Chen
Xiao-rui Chen
Xue-ying Tan
Zong-liang Zhang
Jiang-shui Yuan
Wei-qing Song
Wei-qing Song
author_facet Xiao-rui Chen
Xiao-rui Chen
Xue-ying Tan
Zong-liang Zhang
Jiang-shui Yuan
Wei-qing Song
Wei-qing Song
author_sort Xiao-rui Chen
collection DOAJ
description BackgroundStudies have shown that ESCRT genes affect cell aging, immune environment, and tumors. BRCA was used to explore its effects on tumor prognosis and therapy.MethodsThe data sets of Cancer Genome Atlas (TCGA), Genome-Tissue Expression Plan (GTEX), Human Protein Mapping (HPA), Gene Expression Omnibus (GEO), Clinical Proteomic Tumor Analysis Consortium (CPTAC), R software package, and bioinformatics methods were used to mine the potential carcinogenic effects of ESCRT, including the expression level, prognostic value, and immune value of ESCRT in various types of tumor tissues, and the potential function of ESCRT family genes was further verified in breast cancer.ResultsESCRT showed significant differential expression in various cancers, such as bladder urothelial carcinoma and liver, cervical, renal, esophageal, head, and neck cancers (P <0.05). Abnormal ESCRT expression is associated with poor prognosis in various cancers, such as adrenocortical carcinoma, bladder urothelial carcinoma, breast cancer, and cervical cancer (P <0.05). The expression level of ESCRT was significantly associated with immune cell infiltration and the modulation of the stromal/immune score (all P <0.05). Enrichment analysis showed that ESCRT is associated with immune-related functions and transport signaling pathways in various tumor cells. Moreover, ESCRT serves as an early diagnostic marker for several tumors and is significantly associated with prognosis. This confirms that ESCRT is associated with most immune-infiltrating cells in pan-carcinomas. Taken together, these studies highlight the importance of the ESCRT family gene VPS37D in breast cancer initiation, progression, and immune response.ConclusionThis study highlights ESCRT’s potential in tumor detection via pan-cancer analysis, showing expression variations between tumor and normal tissues, its role in cancer progression through the immune microenvironment, and its specificity and sensitivity in detection. The VPS37D gene, with significant variation in breast cancer, predicts patient prognosis and is related to the tumor microenvironment, suggesting that ESCRT is a novel biomarker for early diagnosis and prognosis assessment.
format Article
id doaj-art-7ca96d8d614849779b903e63f11dd4ba
institution OA Journals
issn 1664-3224
language English
publishDate 2025-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-7ca96d8d614849779b903e63f11dd4ba2025-08-20T02:10:53ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-03-011610.3389/fimmu.2025.15319401531940ESCRT may function as a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancerXiao-rui Chen0Xiao-rui Chen1Xue-ying Tan2Zong-liang Zhang3Jiang-shui Yuan4Wei-qing Song5Wei-qing Song6Qingdao Medical College, Qingdao University, Qingdao, ChinaClinical Laboratory Department, Qingdao Municipal Hospital, Qingdao, ChinaClinical Laboratory Department, Qingdao Municipal Hospital, Qingdao, ChinaDepartment of Urology, Affiliated Hospital of Qingdao University, Qingdao, ChinaClinical Laboratory Department, Qingdao Municipal Hospital, Qingdao, ChinaQingdao Medical College, Qingdao University, Qingdao, ChinaClinical Laboratory Department, Qingdao Municipal Hospital, Qingdao, ChinaBackgroundStudies have shown that ESCRT genes affect cell aging, immune environment, and tumors. BRCA was used to explore its effects on tumor prognosis and therapy.MethodsThe data sets of Cancer Genome Atlas (TCGA), Genome-Tissue Expression Plan (GTEX), Human Protein Mapping (HPA), Gene Expression Omnibus (GEO), Clinical Proteomic Tumor Analysis Consortium (CPTAC), R software package, and bioinformatics methods were used to mine the potential carcinogenic effects of ESCRT, including the expression level, prognostic value, and immune value of ESCRT in various types of tumor tissues, and the potential function of ESCRT family genes was further verified in breast cancer.ResultsESCRT showed significant differential expression in various cancers, such as bladder urothelial carcinoma and liver, cervical, renal, esophageal, head, and neck cancers (P <0.05). Abnormal ESCRT expression is associated with poor prognosis in various cancers, such as adrenocortical carcinoma, bladder urothelial carcinoma, breast cancer, and cervical cancer (P <0.05). The expression level of ESCRT was significantly associated with immune cell infiltration and the modulation of the stromal/immune score (all P <0.05). Enrichment analysis showed that ESCRT is associated with immune-related functions and transport signaling pathways in various tumor cells. Moreover, ESCRT serves as an early diagnostic marker for several tumors and is significantly associated with prognosis. This confirms that ESCRT is associated with most immune-infiltrating cells in pan-carcinomas. Taken together, these studies highlight the importance of the ESCRT family gene VPS37D in breast cancer initiation, progression, and immune response.ConclusionThis study highlights ESCRT’s potential in tumor detection via pan-cancer analysis, showing expression variations between tumor and normal tissues, its role in cancer progression through the immune microenvironment, and its specificity and sensitivity in detection. The VPS37D gene, with significant variation in breast cancer, predicts patient prognosis and is related to the tumor microenvironment, suggesting that ESCRT is a novel biomarker for early diagnosis and prognosis assessment.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1531940/fullpan-cancerESCRTbiomarkerimmune cell infiltrationVPS37D
spellingShingle Xiao-rui Chen
Xiao-rui Chen
Xue-ying Tan
Zong-liang Zhang
Jiang-shui Yuan
Wei-qing Song
Wei-qing Song
ESCRT may function as a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancer
Frontiers in Immunology
pan-cancer
ESCRT
biomarker
immune cell infiltration
VPS37D
title ESCRT may function as a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancer
title_full ESCRT may function as a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancer
title_fullStr ESCRT may function as a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancer
title_full_unstemmed ESCRT may function as a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancer
title_short ESCRT may function as a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancer
title_sort escrt may function as a tumor biomarker transitioning from pan cancer analysis to validation within breast cancer
topic pan-cancer
ESCRT
biomarker
immune cell infiltration
VPS37D
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1531940/full
work_keys_str_mv AT xiaoruichen escrtmayfunctionasatumorbiomarkertransitioningfrompancanceranalysistovalidationwithinbreastcancer
AT xiaoruichen escrtmayfunctionasatumorbiomarkertransitioningfrompancanceranalysistovalidationwithinbreastcancer
AT xueyingtan escrtmayfunctionasatumorbiomarkertransitioningfrompancanceranalysistovalidationwithinbreastcancer
AT zongliangzhang escrtmayfunctionasatumorbiomarkertransitioningfrompancanceranalysistovalidationwithinbreastcancer
AT jiangshuiyuan escrtmayfunctionasatumorbiomarkertransitioningfrompancanceranalysistovalidationwithinbreastcancer
AT weiqingsong escrtmayfunctionasatumorbiomarkertransitioningfrompancanceranalysistovalidationwithinbreastcancer
AT weiqingsong escrtmayfunctionasatumorbiomarkertransitioningfrompancanceranalysistovalidationwithinbreastcancer